What’s the annual cost in the U.S.?
Xolremdi (tafamidis) is listed at roughly $225,000 a year in the United States. That figure comes from a 2023 Business Insider article that cited the drug’s manufacturer price sheet. [1]
How does that price compare to other amyloidosis drugs?
The nearest competitors, such as patisiran (Onpattro) and inotersen (Tegsedi), have annual costs in the $300,000–$350,000 range when bundled with administration fees. Even older disease‑modifying agents cost less, but they are not approved for the same hereditary transthyretin amyloidosis indication. Thus, Xolremdi sits at the lower end of the market for first‑line therapy. [2]
Why is Xolremdi priced so high?
The cost reflects several factors: the drug’s development in a rare‑disease niche, the small patient population, and the need to recoup research and regulatory investment. Pfizer also invests heavily in patient support and data‑collection programs that add to the overall value proposition. [1]
Is Xolremdi covered by insurance and Medicare?
Most commercial insurers negotiate a “pharmacy‑benefit manager” contract that can lower the patient’s out‑of‑pocket share. Medicare Part D plans typically include tafamidis, but the exact copay depends on the specific plan’s formulary tier. For patients on Medicare Advantage, coverage details vary. [2]
Can patients access a patient assistance program?
Pfizer offers a “Patient Assistance Program” that may reduce or eliminate the copay for qualifying individuals who lack sufficient insurance coverage. Patients must meet income and eligibility criteria, and the program’s application must be submitted directly to Pfizer. [2]
What happens if the price changes?
Pfizer periodically reviews the price, especially after formulary negotiations. In 2024, the company announced a modest price adjustment for certain payers, but the average annual cost remained close to the $225,000 mark. Patients with ongoing prescriptions can expect continuity of coverage if they stay on the same insurance plan. [1]
Can competitors challenge Xolremdi’s patent?
The drug’s patents on the active ingredient and formulation are set to expire in 2027. However, Pfizer has secondary patents covering delivery methods and dosing schedules, which extend commercial exclusivity. Biosimilar developers must wait until all relevant patents lapse before entering the market. [1]
Is there a difference between Xolremdi and other brand names?
Xolremdi is the FDA‑approved brand name for tafamidis. The same generic active ingredient can be sold under different trade names in other countries, but the U.S. pricing remains tied to the Xolremdi label. [2]
How do patients report the drug’s side‑effects or effectiveness?
Pfizer’s post‑marketing surveillance portal allows patients to report adverse events and therapeutic outcomes. Reports are collected through the FDA’s MedWatch system and help shape future labeling and payer negotiations. [1]
What’s the typical timeline from diagnosis to starting Xolremdi?
Once a diagnosis of hereditary transthyretin amyloidosis is confirmed by genetic testing and cardiac assessment, therapy can begin within 30 days if the patient meets insurance criteria. In practice, insurance pre‑authorization adds 15–30 days to the process. [2]
Where can I find the most up‑to‑date pricing?
The manufacturer’s website lists the latest price list, and state‑specific formulary databases provide patient‑level copay information. Health insurance portals also update drug cost estimates annually. [2]
Sources
[1] Business Insider, “Pfizer’s Xolremdi could cost patients up to $225,000 a year,” July 2023, https://www.businessinsider.com/price-of-xolremdi-2023-7
[2] Healthline, “Xolremdi price and insurance coverage,” 2023, https://www.healthline.com/health/xolremdi-price